nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluoxetine—ALB—Acitretin—psoriasis	0.0545	0.0827	CbGbCtD
Fluoxetine—CYP3A5—Beclomethasone—psoriasis	0.0515	0.0782	CbGbCtD
Fluoxetine—CYP1A2—Clobetasol propionate—psoriasis	0.0506	0.0768	CbGbCtD
Fluoxetine—CYP2B6—Cholecalciferol—psoriasis	0.03	0.0456	CbGbCtD
Fluoxetine—CYP1A2—Methoxsalen—psoriasis	0.0266	0.0403	CbGbCtD
Fluoxetine—ALB—Mycophenolate mofetil—psoriasis	0.0255	0.0387	CbGbCtD
Fluoxetine—CYP2D6—Hydroxyurea—psoriasis	0.024	0.0363	CbGbCtD
Fluoxetine—CYP3A5—Mycophenolate mofetil—psoriasis	0.0205	0.0311	CbGbCtD
Fluoxetine—ALB—Prednisone—psoriasis	0.0204	0.031	CbGbCtD
Fluoxetine—CYP2C19—Cholecalciferol—psoriasis	0.0191	0.029	CbGbCtD
Fluoxetine—CYP3A4—Calcitriol—psoriasis	0.0179	0.0272	CbGbCtD
Fluoxetine—CYP3A5—Hydrocortisone—psoriasis	0.0165	0.025	CbGbCtD
Fluoxetine—CYP2C9—Cholecalciferol—psoriasis	0.0159	0.0241	CbGbCtD
Fluoxetine—CYP3A5—Cyclosporine—psoriasis	0.0156	0.0236	CbGbCtD
Fluoxetine—CYP2D6—Cholecalciferol—psoriasis	0.0145	0.022	CbGbCtD
Fluoxetine—CYP3A4—Methoxsalen—psoriasis	0.0139	0.0211	CbGbCtD
Fluoxetine—ABCB1—Mycophenolate mofetil—psoriasis	0.0134	0.0203	CbGbCtD
Fluoxetine—CYP2C19—Prednisone—psoriasis	0.0132	0.0201	CbGbCtD
Fluoxetine—CYP2B6—Dexamethasone—psoriasis	0.013	0.0197	CbGbCtD
Fluoxetine—CYP2C19—Cyclosporine—psoriasis	0.0125	0.019	CbGbCtD
Fluoxetine—ABCB1—Betamethasone—psoriasis	0.0115	0.0174	CbGbCtD
Fluoxetine—ABCB1—Prednisolone—psoriasis	0.0113	0.0172	CbGbCtD
Fluoxetine—ABCB1—Hydrocortisone—psoriasis	0.0107	0.0163	CbGbCtD
Fluoxetine—ABCB1—Prednisone—psoriasis	0.0107	0.0162	CbGbCtD
Fluoxetine—CYP2C9—Cyclosporine—psoriasis	0.0104	0.0158	CbGbCtD
Fluoxetine—CYP3A5—Dexamethasone—psoriasis	0.0102	0.0155	CbGbCtD
Fluoxetine—ALB—Methotrexate—psoriasis	0.0102	0.0155	CbGbCtD
Fluoxetine—ABCB1—Cyclosporine—psoriasis	0.0101	0.0154	CbGbCtD
Fluoxetine—CYP2D6—Cyclosporine—psoriasis	0.00954	0.0145	CbGbCtD
Fluoxetine—CYP3A4—Cholecalciferol—psoriasis	0.00923	0.014	CbGbCtD
Fluoxetine—CYP2C19—Dexamethasone—psoriasis	0.00826	0.0125	CbGbCtD
Fluoxetine—CYP3A4—Mycophenolate mofetil—psoriasis	0.008	0.0121	CbGbCtD
Fluoxetine—CYP3A4—Triamcinolone—psoriasis	0.008	0.0121	CbGbCtD
Fluoxetine—CYP2C9—Dexamethasone—psoriasis	0.00687	0.0104	CbGbCtD
Fluoxetine—CYP3A4—Betamethasone—psoriasis	0.00687	0.0104	CbGbCtD
Fluoxetine—CYP3A4—Prednisolone—psoriasis	0.00677	0.0103	CbGbCtD
Fluoxetine—ABCB1—Dexamethasone—psoriasis	0.00667	0.0101	CbGbCtD
Fluoxetine—CYP3A4—Hydrocortisone—psoriasis	0.00642	0.00974	CbGbCtD
Fluoxetine—CYP3A4—Prednisone—psoriasis	0.0064	0.00971	CbGbCtD
Fluoxetine—CYP2D6—Dexamethasone—psoriasis	0.00628	0.00953	CbGbCtD
Fluoxetine—CYP3A4—Cyclosporine—psoriasis	0.00606	0.0092	CbGbCtD
Fluoxetine—ABCB1—Methotrexate—psoriasis	0.00536	0.00813	CbGbCtD
Fluoxetine—CYP3A4—Dexamethasone—psoriasis	0.00399	0.00606	CbGbCtD
Fluoxetine—SIGMAR1—Levonorgestrel—Hydrocortisone—psoriasis	0.000855	1	CbGdCrCtD
Fluoxetine—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000118	0.00414	CbGpPWpGaD
Fluoxetine—CYP2B6—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	0.000118	0.00413	CbGpPWpGaD
Fluoxetine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000116	0.00408	CbGpPWpGaD
Fluoxetine—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000116	0.00407	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000115	0.00404	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—HCAR2—psoriasis	0.000111	0.00391	CbGpPWpGaD
Fluoxetine—CYP2D6—Biological oxidations—CYP2S1—psoriasis	0.00011	0.00386	CbGpPWpGaD
Fluoxetine—SLC6A2—Monoamine Transport—TNF—psoriasis	0.00011	0.00386	CbGpPWpGaD
Fluoxetine—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000109	0.00383	CbGpPWpGaD
Fluoxetine—CYP2D6—Metapathway biotransformation—CYP2S1—psoriasis	0.000108	0.00381	CbGpPWpGaD
Fluoxetine—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000107	0.00377	CbGpPWpGaD
Fluoxetine—CYP2D6—Melatonin metabolism and effects—APOE—psoriasis	0.000107	0.00374	CbGpPWpGaD
Fluoxetine—CYP1A2—Estrogen Receptor Pathway—JUN—psoriasis	0.000106	0.00372	CbGpPWpGaD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL12B—psoriasis	0.000104	0.00364	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—SERPINB8—psoriasis	0.000102	0.0036	CbGpPWpGaD
Fluoxetine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	9.93e-05	0.00349	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—HLA-C—psoriasis	9.92e-05	0.00348	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—IL13—psoriasis	9.86e-05	0.00346	CbGpPWpGaD
Fluoxetine—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—psoriasis	9.79e-05	0.00344	CbGpPWpGaD
Fluoxetine—SLC6A2—SLC-mediated transmembrane transport—CP—psoriasis	9.74e-05	0.00342	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—HCAR2—psoriasis	9.67e-05	0.0034	CbGpPWpGaD
Fluoxetine—SLC6A4—SIDS Susceptibility Pathways—IL10—psoriasis	9.45e-05	0.00332	CbGpPWpGaD
Fluoxetine—CYP1A2—Biological oxidations—CYP2S1—psoriasis	9.31e-05	0.00327	CbGpPWpGaD
Fluoxetine—CYP1A2—Metapathway biotransformation—CYP2S1—psoriasis	9.18e-05	0.00322	CbGpPWpGaD
Fluoxetine—CYP1A2—Estrogen Receptor Pathway—STAT3—psoriasis	9.17e-05	0.00322	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—IL13—psoriasis	9.09e-05	0.00319	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—IL17A—psoriasis	9.07e-05	0.00318	CbGpPWpGaD
Fluoxetine—CYP1A2—Melatonin metabolism and effects—APOE—psoriasis	9.03e-05	0.00317	CbGpPWpGaD
Fluoxetine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.67e-05	0.00305	CbGpPWpGaD
Fluoxetine—ALB—Folate Metabolism—CAT—psoriasis	8.6e-05	0.00302	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—IL12B—psoriasis	8.43e-05	0.00296	CbGpPWpGaD
Fluoxetine—ALB—Vitamin B12 Metabolism—CRP—psoriasis	8.4e-05	0.00295	CbGpPWpGaD
Fluoxetine—ALB—Lipid and lipoprotein metabolism—APOE—psoriasis	8.35e-05	0.00293	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—HLA-E—psoriasis	8.23e-05	0.00289	CbGpPWpGaD
Fluoxetine—ALB—Vitamin B12 Metabolism—APOE—psoriasis	8.22e-05	0.00289	CbGpPWpGaD
Fluoxetine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	8.1e-05	0.00285	CbGpPWpGaD
Fluoxetine—CYP1A2—Tryptophan metabolism—CAT—psoriasis	8.03e-05	0.00282	CbGpPWpGaD
Fluoxetine—ALB—Folate Metabolism—IL4—psoriasis	7.91e-05	0.00278	CbGpPWpGaD
Fluoxetine—ALB—Vitamin B12 Metabolism—ICAM1—psoriasis	7.72e-05	0.00271	CbGpPWpGaD
Fluoxetine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	7.67e-05	0.00269	CbGpPWpGaD
Fluoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	7.6e-05	0.00267	CbGpPWpGaD
Fluoxetine—CYP3A4—Biological oxidations—CYP2S1—psoriasis	7.19e-05	0.00252	CbGpPWpGaD
Fluoxetine—CYP3A4—Metapathway biotransformation—CYP2S1—psoriasis	7.09e-05	0.00249	CbGpPWpGaD
Fluoxetine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	6.92e-05	0.00243	CbGpPWpGaD
Fluoxetine—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	6.89e-05	0.00242	CbGpPWpGaD
Fluoxetine—ALB—Selenium Micronutrient Network—CAT—psoriasis	6.84e-05	0.0024	CbGpPWpGaD
Fluoxetine—ALB—Folate Metabolism—CRP—psoriasis	6.83e-05	0.0024	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	6.81e-05	0.00239	CbGpPWpGaD
Fluoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCL20—psoriasis	6.6e-05	0.00232	CbGpPWpGaD
Fluoxetine—SLC6A4—Circadian rythm related genes—LEP—psoriasis	6.35e-05	0.00223	CbGpPWpGaD
Fluoxetine—CYP2D6—Melatonin metabolism and effects—NFKB1—psoriasis	6.34e-05	0.00223	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—HCAR2—psoriasis	6.29e-05	0.00221	CbGpPWpGaD
Fluoxetine—ALB—Folate Metabolism—ICAM1—psoriasis	6.28e-05	0.0022	CbGpPWpGaD
Fluoxetine—CYP3A4—Tryptophan metabolism—CAT—psoriasis	6.2e-05	0.00218	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—IL10—psoriasis	6.17e-05	0.00216	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—IL4—psoriasis	6e-05	0.00211	CbGpPWpGaD
Fluoxetine—SLC6A4—Circadian rythm related genes—NOS2—psoriasis	5.91e-05	0.00208	CbGpPWpGaD
Fluoxetine—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	5.87e-05	0.00206	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—HLA-B—psoriasis	5.87e-05	0.00206	CbGpPWpGaD
Fluoxetine—ABCB1—HIF-1-alpha transcription factor network—LEP—psoriasis	5.86e-05	0.00206	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—CCL20—psoriasis	5.78e-05	0.00203	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—HCAR2—psoriasis	5.72e-05	0.00201	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—IL10—psoriasis	5.69e-05	0.002	CbGpPWpGaD
Fluoxetine—SLC6A4—Circadian rythm related genes—PPARG—psoriasis	5.53e-05	0.00194	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—HCAR2—psoriasis	5.47e-05	0.00192	CbGpPWpGaD
Fluoxetine—ABCB1—HIF-1-alpha transcription factor network—NOS2—psoriasis	5.46e-05	0.00192	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—HLA-A—psoriasis	5.43e-05	0.00191	CbGpPWpGaD
Fluoxetine—ALB—Selenium Micronutrient Network—CRP—psoriasis	5.43e-05	0.00191	CbGpPWpGaD
Fluoxetine—CYP1A2—Melatonin metabolism and effects—NFKB1—psoriasis	5.37e-05	0.00189	CbGpPWpGaD
Fluoxetine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	5.34e-05	0.00188	CbGpPWpGaD
Fluoxetine—SLC6A4—SIDS Susceptibility Pathways—CXCL8—psoriasis	5.17e-05	0.00181	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—CCL20—psoriasis	5.02e-05	0.00176	CbGpPWpGaD
Fluoxetine—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	4.99e-05	0.00175	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—HLA-DRB1—psoriasis	4.96e-05	0.00174	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—HCAR2—psoriasis	4.96e-05	0.00174	CbGpPWpGaD
Fluoxetine—Hypertension—Betamethasone—psoriasis	4.96e-05	0.000159	CcSEcCtD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—CP—psoriasis	4.95e-05	0.00174	CbGpPWpGaD
Fluoxetine—Paraesthesia—Hydrocortisone—psoriasis	4.93e-05	0.000158	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	4.93e-05	0.000158	CcSEcCtD
Fluoxetine—Urticaria—Cyclosporine—psoriasis	4.91e-05	0.000157	CcSEcCtD
Fluoxetine—ALB—SLC-mediated transmembrane transport—CP—psoriasis	4.9e-05	0.00172	CbGpPWpGaD
Fluoxetine—Myalgia—Betamethasone—psoriasis	4.89e-05	0.000157	CcSEcCtD
Fluoxetine—Myalgia—Dexamethasone—psoriasis	4.89e-05	0.000157	CcSEcCtD
Fluoxetine—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	4.89e-05	0.00172	CbGpPWpGaD
Fluoxetine—Abdominal pain—Cyclosporine—psoriasis	4.88e-05	0.000157	CcSEcCtD
Fluoxetine—Body temperature increased—Cyclosporine—psoriasis	4.88e-05	0.000157	CcSEcCtD
Fluoxetine—Anxiety—Dexamethasone—psoriasis	4.87e-05	0.000156	CcSEcCtD
Fluoxetine—Anxiety—Betamethasone—psoriasis	4.87e-05	0.000156	CcSEcCtD
Fluoxetine—Vomiting—Mycophenolic acid—psoriasis	4.85e-05	0.000156	CcSEcCtD
Fluoxetine—Discomfort—Betamethasone—psoriasis	4.83e-05	0.000155	CcSEcCtD
Fluoxetine—Discomfort—Dexamethasone—psoriasis	4.83e-05	0.000155	CcSEcCtD
Fluoxetine—Dyspepsia—Hydrocortisone—psoriasis	4.83e-05	0.000155	CcSEcCtD
Fluoxetine—Haemoglobin—Methotrexate—psoriasis	4.83e-05	0.000155	CcSEcCtD
Fluoxetine—Rash—Mycophenolic acid—psoriasis	4.81e-05	0.000154	CcSEcCtD
Fluoxetine—Dermatitis—Mycophenolic acid—psoriasis	4.81e-05	0.000154	CcSEcCtD
Fluoxetine—Pain—Prednisolone—psoriasis	4.81e-05	0.000154	CcSEcCtD
Fluoxetine—Hepatitis—Methotrexate—psoriasis	4.8e-05	0.000154	CcSEcCtD
Fluoxetine—Haemorrhage—Methotrexate—psoriasis	4.8e-05	0.000154	CcSEcCtD
Fluoxetine—SLC6A4—SIDS Susceptibility Pathways—JUN—psoriasis	4.8e-05	0.00169	CbGpPWpGaD
Fluoxetine—Urticaria—Mycophenolate mofetil—psoriasis	4.79e-05	0.000154	CcSEcCtD
Fluoxetine—Headache—Mycophenolic acid—psoriasis	4.78e-05	0.000153	CcSEcCtD
Fluoxetine—ALB—Folate Metabolism—IFNG—psoriasis	4.78e-05	0.00168	CbGpPWpGaD
Fluoxetine—Decreased appetite—Hydrocortisone—psoriasis	4.77e-05	0.000153	CcSEcCtD
Fluoxetine—Pharyngitis—Methotrexate—psoriasis	4.77e-05	0.000153	CcSEcCtD
Fluoxetine—Abdominal pain—Mycophenolate mofetil—psoriasis	4.76e-05	0.000153	CcSEcCtD
Fluoxetine—Body temperature increased—Mycophenolate mofetil—psoriasis	4.76e-05	0.000153	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Hydrocortisone—psoriasis	4.74e-05	0.000152	CcSEcCtD
Fluoxetine—Fatigue—Hydrocortisone—psoriasis	4.73e-05	0.000152	CcSEcCtD
Fluoxetine—SLC6A2—Transmembrane transport of small molecules—CARM1—psoriasis	4.72e-05	0.00166	CbGpPWpGaD
Fluoxetine—Musculoskeletal discomfort—Triamcinolone—psoriasis	4.71e-05	0.000151	CcSEcCtD
Fluoxetine—Pain—Hydrocortisone—psoriasis	4.69e-05	0.000151	CcSEcCtD
Fluoxetine—Anaphylactic shock—Dexamethasone—psoriasis	4.69e-05	0.00015	CcSEcCtD
Fluoxetine—Anaphylactic shock—Betamethasone—psoriasis	4.69e-05	0.00015	CcSEcCtD
Fluoxetine—Insomnia—Triamcinolone—psoriasis	4.67e-05	0.00015	CcSEcCtD
Fluoxetine—Infection—Betamethasone—psoriasis	4.66e-05	0.000149	CcSEcCtD
Fluoxetine—Infection—Dexamethasone—psoriasis	4.66e-05	0.000149	CcSEcCtD
Fluoxetine—Ill-defined disorder—Prednisone—psoriasis	4.64e-05	0.000149	CcSEcCtD
Fluoxetine—Paraesthesia—Triamcinolone—psoriasis	4.64e-05	0.000149	CcSEcCtD
Fluoxetine—Feeling abnormal—Prednisolone—psoriasis	4.63e-05	0.000149	CcSEcCtD
Fluoxetine—Visual impairment—Methotrexate—psoriasis	4.63e-05	0.000149	CcSEcCtD
Fluoxetine—Anaemia—Prednisone—psoriasis	4.62e-05	0.000148	CcSEcCtD
Fluoxetine—SLC6A4—SIDS Susceptibility Pathways—NFKB1—psoriasis	4.62e-05	0.00162	CbGpPWpGaD
Fluoxetine—Shock—Dexamethasone—psoriasis	4.61e-05	0.000148	CcSEcCtD
Fluoxetine—Shock—Betamethasone—psoriasis	4.61e-05	0.000148	CcSEcCtD
Fluoxetine—Dyspnoea—Triamcinolone—psoriasis	4.61e-05	0.000148	CcSEcCtD
Fluoxetine—Agitation—Prednisone—psoriasis	4.6e-05	0.000148	CcSEcCtD
Fluoxetine—Thrombocytopenia—Dexamethasone—psoriasis	4.59e-05	0.000147	CcSEcCtD
Fluoxetine—Thrombocytopenia—Betamethasone—psoriasis	4.59e-05	0.000147	CcSEcCtD
Fluoxetine—Tachycardia—Betamethasone—psoriasis	4.58e-05	0.000147	CcSEcCtD
Fluoxetine—Tachycardia—Dexamethasone—psoriasis	4.58e-05	0.000147	CcSEcCtD
Fluoxetine—Angioedema—Prednisone—psoriasis	4.57e-05	0.000147	CcSEcCtD
Fluoxetine—Hypersensitivity—Cyclosporine—psoriasis	4.55e-05	0.000146	CcSEcCtD
Fluoxetine—Dyspepsia—Triamcinolone—psoriasis	4.55e-05	0.000146	CcSEcCtD
Fluoxetine—Erythema multiforme—Methotrexate—psoriasis	4.54e-05	0.000146	CcSEcCtD
Fluoxetine—Nausea—Mycophenolic acid—psoriasis	4.53e-05	0.000146	CcSEcCtD
Fluoxetine—Hyperhidrosis—Dexamethasone—psoriasis	4.53e-05	0.000145	CcSEcCtD
Fluoxetine—Hyperhidrosis—Betamethasone—psoriasis	4.53e-05	0.000145	CcSEcCtD
Fluoxetine—Feeling abnormal—Hydrocortisone—psoriasis	4.52e-05	0.000145	CcSEcCtD
Fluoxetine—Malaise—Prednisone—psoriasis	4.51e-05	0.000145	CcSEcCtD
Fluoxetine—Vertigo—Prednisone—psoriasis	4.5e-05	0.000144	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Hydrocortisone—psoriasis	4.49e-05	0.000144	CcSEcCtD
Fluoxetine—Syncope—Prednisone—psoriasis	4.49e-05	0.000144	CcSEcCtD
Fluoxetine—Tinnitus—Methotrexate—psoriasis	4.48e-05	0.000144	CcSEcCtD
Fluoxetine—Anorexia—Dexamethasone—psoriasis	4.47e-05	0.000143	CcSEcCtD
Fluoxetine—Anorexia—Betamethasone—psoriasis	4.47e-05	0.000143	CcSEcCtD
Fluoxetine—Urticaria—Prednisolone—psoriasis	4.46e-05	0.000143	CcSEcCtD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—psoriasis	4.46e-05	0.00157	CbGpPWpGaD
Fluoxetine—Fatigue—Triamcinolone—psoriasis	4.46e-05	0.000143	CcSEcCtD
Fluoxetine—Hypersensitivity—Mycophenolate mofetil—psoriasis	4.44e-05	0.000142	CcSEcCtD
Fluoxetine—Asthenia—Cyclosporine—psoriasis	4.43e-05	0.000142	CcSEcCtD
Fluoxetine—Pain—Triamcinolone—psoriasis	4.42e-05	0.000142	CcSEcCtD
Fluoxetine—Loss of consciousness—Prednisone—psoriasis	4.4e-05	0.000141	CcSEcCtD
Fluoxetine—Hypotension—Dexamethasone—psoriasis	4.38e-05	0.000141	CcSEcCtD
Fluoxetine—Hypotension—Betamethasone—psoriasis	4.38e-05	0.000141	CcSEcCtD
Fluoxetine—Pruritus—Cyclosporine—psoriasis	4.37e-05	0.00014	CcSEcCtD
Fluoxetine—Urticaria—Hydrocortisone—psoriasis	4.36e-05	0.00014	CcSEcCtD
Fluoxetine—Abdominal pain—Hydrocortisone—psoriasis	4.34e-05	0.000139	CcSEcCtD
Fluoxetine—Body temperature increased—Hydrocortisone—psoriasis	4.34e-05	0.000139	CcSEcCtD
Fluoxetine—Convulsion—Prednisone—psoriasis	4.34e-05	0.000139	CcSEcCtD
Fluoxetine—Asthenia—Mycophenolate mofetil—psoriasis	4.32e-05	0.000139	CcSEcCtD
Fluoxetine—Hypertension—Prednisone—psoriasis	4.32e-05	0.000139	CcSEcCtD
Fluoxetine—Chills—Methotrexate—psoriasis	4.31e-05	0.000138	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Betamethasone—psoriasis	4.27e-05	0.000137	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Dexamethasone—psoriasis	4.27e-05	0.000137	CcSEcCtD
Fluoxetine—Pruritus—Mycophenolate mofetil—psoriasis	4.26e-05	0.000137	CcSEcCtD
Fluoxetine—Arthralgia—Prednisone—psoriasis	4.26e-05	0.000137	CcSEcCtD
Fluoxetine—Myalgia—Prednisone—psoriasis	4.26e-05	0.000137	CcSEcCtD
Fluoxetine—Feeling abnormal—Triamcinolone—psoriasis	4.26e-05	0.000137	CcSEcCtD
Fluoxetine—Anxiety—Prednisone—psoriasis	4.24e-05	0.000136	CcSEcCtD
Fluoxetine—Alopecia—Methotrexate—psoriasis	4.24e-05	0.000136	CcSEcCtD
Fluoxetine—Insomnia—Betamethasone—psoriasis	4.24e-05	0.000136	CcSEcCtD
Fluoxetine—Insomnia—Dexamethasone—psoriasis	4.24e-05	0.000136	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	4.23e-05	0.000136	CcSEcCtD
Fluoxetine—Diarrhoea—Cyclosporine—psoriasis	4.23e-05	0.000136	CcSEcCtD
Fluoxetine—Paraesthesia—Betamethasone—psoriasis	4.21e-05	0.000135	CcSEcCtD
Fluoxetine—Paraesthesia—Dexamethasone—psoriasis	4.21e-05	0.000135	CcSEcCtD
Fluoxetine—Discomfort—Prednisone—psoriasis	4.21e-05	0.000135	CcSEcCtD
Fluoxetine—Mental disorder—Methotrexate—psoriasis	4.21e-05	0.000135	CcSEcCtD
Fluoxetine—SLC6A4—SIDS Susceptibility Pathways—VEGFA—psoriasis	4.2e-05	0.00147	CbGpPWpGaD
Fluoxetine—Malnutrition—Methotrexate—psoriasis	4.18e-05	0.000134	CcSEcCtD
Fluoxetine—Hypersensitivity—Prednisolone—psoriasis	4.14e-05	0.000133	CcSEcCtD
Fluoxetine—Dyspepsia—Dexamethasone—psoriasis	4.13e-05	0.000132	CcSEcCtD
Fluoxetine—Dyspepsia—Betamethasone—psoriasis	4.13e-05	0.000132	CcSEcCtD
Fluoxetine—Diarrhoea—Mycophenolate mofetil—psoriasis	4.12e-05	0.000132	CcSEcCtD
Fluoxetine—Urticaria—Triamcinolone—psoriasis	4.11e-05	0.000132	CcSEcCtD
Fluoxetine—Dysgeusia—Methotrexate—psoriasis	4.09e-05	0.000131	CcSEcCtD
Fluoxetine—Body temperature increased—Triamcinolone—psoriasis	4.09e-05	0.000131	CcSEcCtD
Fluoxetine—Dizziness—Cyclosporine—psoriasis	4.08e-05	0.000131	CcSEcCtD
Fluoxetine—Anaphylactic shock—Prednisone—psoriasis	4.08e-05	0.000131	CcSEcCtD
Fluoxetine—Decreased appetite—Dexamethasone—psoriasis	4.08e-05	0.000131	CcSEcCtD
Fluoxetine—Decreased appetite—Betamethasone—psoriasis	4.08e-05	0.000131	CcSEcCtD
Fluoxetine—Infection—Prednisone—psoriasis	4.06e-05	0.00013	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Dexamethasone—psoriasis	4.05e-05	0.00013	CcSEcCtD
Fluoxetine—Gastrointestinal disorder—Betamethasone—psoriasis	4.05e-05	0.00013	CcSEcCtD
Fluoxetine—Back pain—Methotrexate—psoriasis	4.04e-05	0.00013	CcSEcCtD
Fluoxetine—Hypersensitivity—Hydrocortisone—psoriasis	4.04e-05	0.00013	CcSEcCtD
Fluoxetine—Fatigue—Betamethasone—psoriasis	4.04e-05	0.00013	CcSEcCtD
Fluoxetine—Fatigue—Dexamethasone—psoriasis	4.04e-05	0.00013	CcSEcCtD
Fluoxetine—Shock—Prednisone—psoriasis	4.02e-05	0.000129	CcSEcCtD
Fluoxetine—Pain—Betamethasone—psoriasis	4.01e-05	0.000129	CcSEcCtD
Fluoxetine—Pain—Dexamethasone—psoriasis	4.01e-05	0.000129	CcSEcCtD
Fluoxetine—Tachycardia—Prednisone—psoriasis	3.99e-05	0.000128	CcSEcCtD
Fluoxetine—Dizziness—Mycophenolate mofetil—psoriasis	3.98e-05	0.000128	CcSEcCtD
Fluoxetine—ALB—Folate Metabolism—NFKB1—psoriasis	3.98e-05	0.0014	CbGpPWpGaD
Fluoxetine—Skin disorder—Prednisone—psoriasis	3.97e-05	0.000127	CcSEcCtD
Fluoxetine—Hyperhidrosis—Prednisone—psoriasis	3.95e-05	0.000127	CcSEcCtD
Fluoxetine—Asthenia—Hydrocortisone—psoriasis	3.94e-05	0.000126	CcSEcCtD
Fluoxetine—Vomiting—Cyclosporine—psoriasis	3.93e-05	0.000126	CcSEcCtD
Fluoxetine—SLC6A4—Circadian rythm related genes—JUN—psoriasis	3.92e-05	0.00138	CbGpPWpGaD
Fluoxetine—Rash—Cyclosporine—psoriasis	3.89e-05	0.000125	CcSEcCtD
Fluoxetine—Anorexia—Prednisone—psoriasis	3.89e-05	0.000125	CcSEcCtD
Fluoxetine—Dermatitis—Cyclosporine—psoriasis	3.89e-05	0.000125	CcSEcCtD
Fluoxetine—Pruritus—Hydrocortisone—psoriasis	3.88e-05	0.000125	CcSEcCtD
Fluoxetine—Ill-defined disorder—Methotrexate—psoriasis	3.88e-05	0.000125	CcSEcCtD
Fluoxetine—Headache—Cyclosporine—psoriasis	3.87e-05	0.000124	CcSEcCtD
Fluoxetine—Anaemia—Methotrexate—psoriasis	3.86e-05	0.000124	CcSEcCtD
Fluoxetine—Feeling abnormal—Dexamethasone—psoriasis	3.86e-05	0.000124	CcSEcCtD
Fluoxetine—Feeling abnormal—Betamethasone—psoriasis	3.86e-05	0.000124	CcSEcCtD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—psoriasis	3.86e-05	0.00135	CbGpPWpGaD
Fluoxetine—Gastrointestinal pain—Dexamethasone—psoriasis	3.83e-05	0.000123	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Betamethasone—psoriasis	3.83e-05	0.000123	CcSEcCtD
Fluoxetine—Vomiting—Mycophenolate mofetil—psoriasis	3.83e-05	0.000123	CcSEcCtD
Fluoxetine—Hypersensitivity—Triamcinolone—psoriasis	3.81e-05	0.000122	CcSEcCtD
Fluoxetine—ALB—Vitamin B12 Metabolism—TNF—psoriasis	3.8e-05	0.00133	CbGpPWpGaD
Fluoxetine—Rash—Mycophenolate mofetil—psoriasis	3.8e-05	0.000122	CcSEcCtD
Fluoxetine—ALB—Selenium Micronutrient Network—IFNG—psoriasis	3.8e-05	0.00133	CbGpPWpGaD
Fluoxetine—Dermatitis—Mycophenolate mofetil—psoriasis	3.79e-05	0.000122	CcSEcCtD
Fluoxetine—Headache—Mycophenolate mofetil—psoriasis	3.77e-05	0.000121	CcSEcCtD
Fluoxetine—Malaise—Methotrexate—psoriasis	3.77e-05	0.000121	CcSEcCtD
Fluoxetine—Vertigo—Methotrexate—psoriasis	3.76e-05	0.000121	CcSEcCtD
Fluoxetine—Diarrhoea—Hydrocortisone—psoriasis	3.76e-05	0.000121	CcSEcCtD
Fluoxetine—Leukopenia—Methotrexate—psoriasis	3.74e-05	0.00012	CcSEcCtD
Fluoxetine—Urticaria—Dexamethasone—psoriasis	3.72e-05	0.00012	CcSEcCtD
Fluoxetine—Urticaria—Betamethasone—psoriasis	3.72e-05	0.00012	CcSEcCtD
Fluoxetine—Musculoskeletal discomfort—Prednisone—psoriasis	3.72e-05	0.000119	CcSEcCtD
Fluoxetine—Dizziness—Prednisolone—psoriasis	3.72e-05	0.000119	CcSEcCtD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	3.71e-05	0.0013	CbGpPWpGaD
Fluoxetine—Asthenia—Triamcinolone—psoriasis	3.71e-05	0.000119	CcSEcCtD
Fluoxetine—Abdominal pain—Betamethasone—psoriasis	3.71e-05	0.000119	CcSEcCtD
Fluoxetine—Body temperature increased—Dexamethasone—psoriasis	3.71e-05	0.000119	CcSEcCtD
Fluoxetine—Body temperature increased—Betamethasone—psoriasis	3.71e-05	0.000119	CcSEcCtD
Fluoxetine—Abdominal pain—Dexamethasone—psoriasis	3.71e-05	0.000119	CcSEcCtD
Fluoxetine—Insomnia—Prednisone—psoriasis	3.69e-05	0.000119	CcSEcCtD
Fluoxetine—Nausea—Cyclosporine—psoriasis	3.67e-05	0.000118	CcSEcCtD
Fluoxetine—Paraesthesia—Prednisone—psoriasis	3.67e-05	0.000118	CcSEcCtD
Fluoxetine—Pruritus—Triamcinolone—psoriasis	3.66e-05	0.000117	CcSEcCtD
Fluoxetine—Cough—Methotrexate—psoriasis	3.65e-05	0.000117	CcSEcCtD
Fluoxetine—Dizziness—Hydrocortisone—psoriasis	3.63e-05	0.000116	CcSEcCtD
Fluoxetine—ABCB1—Allograft Rejection—IFNG—psoriasis	3.63e-05	0.00127	CbGpPWpGaD
Fluoxetine—Convulsion—Methotrexate—psoriasis	3.62e-05	0.000116	CcSEcCtD
Fluoxetine—ABCB1—HIF-1-alpha transcription factor network—JUN—psoriasis	3.62e-05	0.00127	CbGpPWpGaD
Fluoxetine—SLC6A4—SIDS Susceptibility Pathways—TNF—psoriasis	3.6e-05	0.00126	CbGpPWpGaD
Fluoxetine—Dyspepsia—Prednisone—psoriasis	3.59e-05	0.000115	CcSEcCtD
Fluoxetine—Nausea—Mycophenolate mofetil—psoriasis	3.58e-05	0.000115	CcSEcCtD
Fluoxetine—Chest pain—Methotrexate—psoriasis	3.56e-05	0.000114	CcSEcCtD
Fluoxetine—Myalgia—Methotrexate—psoriasis	3.56e-05	0.000114	CcSEcCtD
Fluoxetine—Arthralgia—Methotrexate—psoriasis	3.56e-05	0.000114	CcSEcCtD
Fluoxetine—Decreased appetite—Prednisone—psoriasis	3.55e-05	0.000114	CcSEcCtD
Fluoxetine—Rash—Prednisolone—psoriasis	3.54e-05	0.000114	CcSEcCtD
Fluoxetine—Dermatitis—Prednisolone—psoriasis	3.54e-05	0.000114	CcSEcCtD
Fluoxetine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	3.54e-05	0.000113	CcSEcCtD
Fluoxetine—Fatigue—Prednisone—psoriasis	3.52e-05	0.000113	CcSEcCtD
Fluoxetine—Headache—Prednisolone—psoriasis	3.52e-05	0.000113	CcSEcCtD
Fluoxetine—Discomfort—Methotrexate—psoriasis	3.52e-05	0.000113	CcSEcCtD
Fluoxetine—Constipation—Prednisone—psoriasis	3.49e-05	0.000112	CcSEcCtD
Fluoxetine—Vomiting—Hydrocortisone—psoriasis	3.49e-05	0.000112	CcSEcCtD
Fluoxetine—Rash—Hydrocortisone—psoriasis	3.46e-05	0.000111	CcSEcCtD
Fluoxetine—Dermatitis—Hydrocortisone—psoriasis	3.46e-05	0.000111	CcSEcCtD
Fluoxetine—Confusional state—Methotrexate—psoriasis	3.44e-05	0.00011	CcSEcCtD
Fluoxetine—Headache—Hydrocortisone—psoriasis	3.44e-05	0.00011	CcSEcCtD
Fluoxetine—Dizziness—Triamcinolone—psoriasis	3.42e-05	0.00011	CcSEcCtD
Fluoxetine—Anaphylactic shock—Methotrexate—psoriasis	3.41e-05	0.00011	CcSEcCtD
Fluoxetine—Infection—Methotrexate—psoriasis	3.39e-05	0.000109	CcSEcCtD
Fluoxetine—HTR2C—Signaling Pathways—HCAR2—psoriasis	3.38e-05	0.00119	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—CXCL8—psoriasis	3.37e-05	0.00118	CbGpPWpGaD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—psoriasis	3.37e-05	0.00118	CbGpPWpGaD
Fluoxetine—Feeling abnormal—Prednisone—psoriasis	3.36e-05	0.000108	CcSEcCtD
Fluoxetine—Asthenia—Dexamethasone—psoriasis	3.36e-05	0.000108	CcSEcCtD
Fluoxetine—Asthenia—Betamethasone—psoriasis	3.36e-05	0.000108	CcSEcCtD
Fluoxetine—Thrombocytopenia—Methotrexate—psoriasis	3.34e-05	0.000107	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Prednisone—psoriasis	3.34e-05	0.000107	CcSEcCtD
Fluoxetine—Nausea—Prednisolone—psoriasis	3.34e-05	0.000107	CcSEcCtD
Fluoxetine—Pruritus—Betamethasone—psoriasis	3.32e-05	0.000106	CcSEcCtD
Fluoxetine—Pruritus—Dexamethasone—psoriasis	3.32e-05	0.000106	CcSEcCtD
Fluoxetine—Skin disorder—Methotrexate—psoriasis	3.31e-05	0.000106	CcSEcCtD
Fluoxetine—Hyperhidrosis—Methotrexate—psoriasis	3.3e-05	0.000106	CcSEcCtD
Fluoxetine—Vomiting—Triamcinolone—psoriasis	3.29e-05	0.000105	CcSEcCtD
Fluoxetine—HTR2C—GPCR downstream signaling—CCL20—psoriasis	3.27e-05	0.00115	CbGpPWpGaD
Fluoxetine—Nausea—Hydrocortisone—psoriasis	3.26e-05	0.000105	CcSEcCtD
Fluoxetine—Rash—Triamcinolone—psoriasis	3.26e-05	0.000105	CcSEcCtD
Fluoxetine—Dermatitis—Triamcinolone—psoriasis	3.26e-05	0.000104	CcSEcCtD
Fluoxetine—Anorexia—Methotrexate—psoriasis	3.25e-05	0.000104	CcSEcCtD
Fluoxetine—Urticaria—Prednisone—psoriasis	3.24e-05	0.000104	CcSEcCtD
Fluoxetine—Headache—Triamcinolone—psoriasis	3.24e-05	0.000104	CcSEcCtD
Fluoxetine—Abdominal pain—Prednisone—psoriasis	3.23e-05	0.000104	CcSEcCtD
Fluoxetine—Body temperature increased—Prednisone—psoriasis	3.23e-05	0.000104	CcSEcCtD
Fluoxetine—Diarrhoea—Betamethasone—psoriasis	3.21e-05	0.000103	CcSEcCtD
Fluoxetine—Diarrhoea—Dexamethasone—psoriasis	3.21e-05	0.000103	CcSEcCtD
Fluoxetine—Hypotension—Methotrexate—psoriasis	3.19e-05	0.000102	CcSEcCtD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	3.18e-05	0.00112	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—NDUFA5—psoriasis	3.18e-05	0.00112	CbGpPWpGaD
Fluoxetine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	3.16e-05	0.00111	CbGpPWpGaD
Fluoxetine—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	3.16e-05	0.00111	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—CXCL8—psoriasis	3.11e-05	0.00109	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—NDUFA5—psoriasis	3.11e-05	0.00109	CbGpPWpGaD
Fluoxetine—Musculoskeletal discomfort—Methotrexate—psoriasis	3.11e-05	9.98e-05	CcSEcCtD
Fluoxetine—Dizziness—Dexamethasone—psoriasis	3.1e-05	9.95e-05	CcSEcCtD
Fluoxetine—Dizziness—Betamethasone—psoriasis	3.1e-05	9.95e-05	CcSEcCtD
Fluoxetine—ALB—Platelet degranulation—VEGFA—psoriasis	3.09e-05	0.00109	CbGpPWpGaD
Fluoxetine—ALB—Folate Metabolism—TNF—psoriasis	3.09e-05	0.00109	CbGpPWpGaD
Fluoxetine—Insomnia—Methotrexate—psoriasis	3.09e-05	9.91e-05	CcSEcCtD
Fluoxetine—Nausea—Triamcinolone—psoriasis	3.07e-05	9.85e-05	CcSEcCtD
Fluoxetine—ALB—Vitamin B12 Metabolism—IL6—psoriasis	3.07e-05	0.00108	CbGpPWpGaD
Fluoxetine—Paraesthesia—Methotrexate—psoriasis	3.06e-05	9.83e-05	CcSEcCtD
Fluoxetine—Dyspnoea—Methotrexate—psoriasis	3.04e-05	9.76e-05	CcSEcCtD
Fluoxetine—Somnolence—Methotrexate—psoriasis	3.03e-05	9.74e-05	CcSEcCtD
Fluoxetine—Hypersensitivity—Prednisone—psoriasis	3.01e-05	9.65e-05	CcSEcCtD
Fluoxetine—Dyspepsia—Methotrexate—psoriasis	3e-05	9.64e-05	CcSEcCtD
Fluoxetine—Vomiting—Dexamethasone—psoriasis	2.98e-05	9.57e-05	CcSEcCtD
Fluoxetine—Vomiting—Betamethasone—psoriasis	2.98e-05	9.57e-05	CcSEcCtD
Fluoxetine—ALB—Hemostasis—ITGAL—psoriasis	2.98e-05	0.00105	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—CCL20—psoriasis	2.97e-05	0.00104	CbGpPWpGaD
Fluoxetine—Decreased appetite—Methotrexate—psoriasis	2.97e-05	9.52e-05	CcSEcCtD
Fluoxetine—Rash—Dexamethasone—psoriasis	2.96e-05	9.49e-05	CcSEcCtD
Fluoxetine—Rash—Betamethasone—psoriasis	2.96e-05	9.49e-05	CcSEcCtD
Fluoxetine—Dermatitis—Betamethasone—psoriasis	2.95e-05	9.48e-05	CcSEcCtD
Fluoxetine—Dermatitis—Dexamethasone—psoriasis	2.95e-05	9.48e-05	CcSEcCtD
Fluoxetine—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	2.95e-05	0.00103	CbGpPWpGaD
Fluoxetine—Gastrointestinal disorder—Methotrexate—psoriasis	2.95e-05	9.45e-05	CcSEcCtD
Fluoxetine—Fatigue—Methotrexate—psoriasis	2.94e-05	9.44e-05	CcSEcCtD
Fluoxetine—Headache—Dexamethasone—psoriasis	2.94e-05	9.43e-05	CcSEcCtD
Fluoxetine—Headache—Betamethasone—psoriasis	2.94e-05	9.43e-05	CcSEcCtD
Fluoxetine—HTR2A—Signaling Pathways—HCAR2—psoriasis	2.93e-05	0.00103	CbGpPWpGaD
Fluoxetine—Asthenia—Prednisone—psoriasis	2.93e-05	9.4e-05	CcSEcCtD
Fluoxetine—HTR2C—Signaling Pathways—TAGAP—psoriasis	2.93e-05	0.00103	CbGpPWpGaD
Fluoxetine—Pain—Methotrexate—psoriasis	2.92e-05	9.37e-05	CcSEcCtD
Fluoxetine—SLC6A4—SIDS Susceptibility Pathways—IL6—psoriasis	2.9e-05	0.00102	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—JUN—psoriasis	2.89e-05	0.00101	CbGpPWpGaD
Fluoxetine—Pruritus—Prednisone—psoriasis	2.89e-05	9.27e-05	CcSEcCtD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—psoriasis	2.89e-05	0.00101	CbGpPWpGaD
Fluoxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—psoriasis	2.89e-05	0.00101	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—CCL20—psoriasis	2.84e-05	0.000997	CbGpPWpGaD
Fluoxetine—Feeling abnormal—Methotrexate—psoriasis	2.81e-05	9.02e-05	CcSEcCtD
Fluoxetine—Diarrhoea—Prednisone—psoriasis	2.79e-05	8.97e-05	CcSEcCtD
Fluoxetine—Gastrointestinal pain—Methotrexate—psoriasis	2.79e-05	8.96e-05	CcSEcCtD
Fluoxetine—Nausea—Dexamethasone—psoriasis	2.79e-05	8.94e-05	CcSEcCtD
Fluoxetine—Nausea—Betamethasone—psoriasis	2.79e-05	8.94e-05	CcSEcCtD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—NFKB1—psoriasis	2.78e-05	0.000977	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	2.78e-05	0.000975	CbGpPWpGaD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—TYK2—psoriasis	2.76e-05	0.00097	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—VEGFA—psoriasis	2.74e-05	0.000961	CbGpPWpGaD
Fluoxetine—ALB—Folate Metabolism—TP53—psoriasis	2.73e-05	0.000957	CbGpPWpGaD
Fluoxetine—Urticaria—Methotrexate—psoriasis	2.71e-05	8.7e-05	CcSEcCtD
Fluoxetine—CYP2B6—Metabolism—CYP2S1—psoriasis	2.7e-05	0.00095	CbGpPWpGaD
Fluoxetine—Dizziness—Prednisone—psoriasis	2.7e-05	8.67e-05	CcSEcCtD
Fluoxetine—Abdominal pain—Methotrexate—psoriasis	2.7e-05	8.66e-05	CcSEcCtD
Fluoxetine—Body temperature increased—Methotrexate—psoriasis	2.7e-05	8.66e-05	CcSEcCtD
Fluoxetine—ALB—Metabolism—NDUFA5—psoriasis	2.68e-05	0.00094	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CYP2S1—psoriasis	2.64e-05	0.000928	CbGpPWpGaD
Fluoxetine—Vomiting—Prednisone—psoriasis	2.6e-05	8.33e-05	CcSEcCtD
Fluoxetine—SLC6A4—Circadian rythm related genes—TP53—psoriasis	2.59e-05	0.000909	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—CCL20—psoriasis	2.58e-05	0.000905	CbGpPWpGaD
Fluoxetine—Rash—Prednisone—psoriasis	2.57e-05	8.26e-05	CcSEcCtD
Fluoxetine—Dermatitis—Prednisone—psoriasis	2.57e-05	8.25e-05	CcSEcCtD
Fluoxetine—Headache—Prednisone—psoriasis	2.56e-05	8.21e-05	CcSEcCtD
Fluoxetine—HTR2A—Signaling Pathways—TAGAP—psoriasis	2.54e-05	0.000893	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—VEGFA—psoriasis	2.53e-05	0.000887	CbGpPWpGaD
Fluoxetine—Hypersensitivity—Methotrexate—psoriasis	2.51e-05	8.07e-05	CcSEcCtD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.5e-05	0.000877	CbGpPWpGaD
Fluoxetine—ALB—Folate Metabolism—IL6—psoriasis	2.5e-05	0.000876	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—CP—psoriasis	2.49e-05	0.000874	CbGpPWpGaD
Fluoxetine—ALB—Selenium Micronutrient Network—TNF—psoriasis	2.46e-05	0.000863	CbGpPWpGaD
Fluoxetine—Asthenia—Methotrexate—psoriasis	2.45e-05	7.86e-05	CcSEcCtD
Fluoxetine—Nausea—Prednisone—psoriasis	2.43e-05	7.78e-05	CcSEcCtD
Fluoxetine—Pruritus—Methotrexate—psoriasis	2.41e-05	7.75e-05	CcSEcCtD
Fluoxetine—CYP2C19—Metabolism—NDUFA5—psoriasis	2.4e-05	0.000844	CbGpPWpGaD
Fluoxetine—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	2.37e-05	0.000834	CbGpPWpGaD
Fluoxetine—SLC6A4—Circadian rythm related genes—IL6—psoriasis	2.37e-05	0.000832	CbGpPWpGaD
Fluoxetine—ABCB1—Allograft Rejection—TNF—psoriasis	2.35e-05	0.000824	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—NDUFA5—psoriasis	2.35e-05	0.000824	CbGpPWpGaD
Fluoxetine—Diarrhoea—Methotrexate—psoriasis	2.33e-05	7.49e-05	CcSEcCtD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	2.33e-05	0.000819	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CYP2S1—psoriasis	2.28e-05	0.000799	CbGpPWpGaD
Fluoxetine—Dizziness—Methotrexate—psoriasis	2.26e-05	7.24e-05	CcSEcCtD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.24e-05	0.000787	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—NDUFA5—psoriasis	2.21e-05	0.000776	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—NDUFA5—psoriasis	2.19e-05	0.00077	CbGpPWpGaD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	2.18e-05	0.000766	CbGpPWpGaD
Fluoxetine—Vomiting—Methotrexate—psoriasis	2.17e-05	6.96e-05	CcSEcCtD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—TNF—psoriasis	2.16e-05	0.00076	CbGpPWpGaD
Fluoxetine—Rash—Methotrexate—psoriasis	2.15e-05	6.91e-05	CcSEcCtD
Fluoxetine—Dermatitis—Methotrexate—psoriasis	2.15e-05	6.9e-05	CcSEcCtD
Fluoxetine—Headache—Methotrexate—psoriasis	2.14e-05	6.86e-05	CcSEcCtD
Fluoxetine—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	2.08e-05	0.00073	CbGpPWpGaD
Fluoxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	2.05e-05	0.00072	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CYP2S1—psoriasis	2.04e-05	0.000718	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.04e-05	0.000718	CbGpPWpGaD
Fluoxetine—Nausea—Methotrexate—psoriasis	2.03e-05	6.51e-05	CcSEcCtD
Fluoxetine—ABCB1—Metabolism—CYP2S1—psoriasis	1.99e-05	0.0007	CbGpPWpGaD
Fluoxetine—ALB—Selenium Micronutrient Network—IL6—psoriasis	1.98e-05	0.000696	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CYP2S1—psoriasis	1.88e-05	0.00066	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—NDUFA5—psoriasis	1.87e-05	0.000658	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CYP2S1—psoriasis	1.86e-05	0.000654	CbGpPWpGaD
Fluoxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	1.78e-05	0.000625	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CCL20—psoriasis	1.75e-05	0.000616	CbGpPWpGaD
Fluoxetine—HTR2A—SIDS Susceptibility Pathways—IL6—psoriasis	1.75e-05	0.000613	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—CARM1—psoriasis	1.75e-05	0.000613	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CYP2S1—psoriasis	1.59e-05	0.000559	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR ligand binding—CXCL8—psoriasis	1.56e-05	0.000548	CbGpPWpGaD
Fluoxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.56e-05	0.000546	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	1.55e-05	0.000543	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CCL20—psoriasis	1.52e-05	0.000535	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	1.49e-05	0.000523	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—NDUFA5—psoriasis	1.45e-05	0.000508	CbGpPWpGaD
Fluoxetine—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	1.37e-05	0.000482	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR ligand binding—CXCL8—psoriasis	1.36e-05	0.000476	CbGpPWpGaD
Fluoxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	1.35e-05	0.000474	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	1.35e-05	0.000474	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CARM1—psoriasis	1.32e-05	0.000464	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CARM1—psoriasis	1.29e-05	0.000453	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CYP2S1—psoriasis	1.23e-05	0.000432	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—NOS2—psoriasis	1.22e-05	0.000429	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.19e-05	0.000419	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	1.16e-05	0.000407	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CARM1—psoriasis	1.11e-05	0.00039	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.07e-05	0.000376	CbGpPWpGaD
Fluoxetine—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.04e-05	0.000365	CbGpPWpGaD
Fluoxetine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.02e-05	0.000358	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CARM1—psoriasis	9.98e-06	0.00035	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	9.77e-06	0.000343	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CARM1—psoriasis	9.74e-06	0.000342	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—SOCS1—psoriasis	9.66e-06	0.000339	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.33e-06	0.000328	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—TYK2—psoriasis	9.21e-06	0.000323	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CARM1—psoriasis	9.18e-06	0.000322	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CARM1—psoriasis	9.1e-06	0.00032	CbGpPWpGaD
Fluoxetine—HTR2C—GPCR downstream signaling—CXCL8—psoriasis	8.83e-06	0.00031	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	8.51e-06	0.000299	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—SOCS1—psoriasis	8.39e-06	0.000294	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	8.35e-06	0.000293	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—CAT—psoriasis	8.12e-06	0.000285	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—CXCL8—psoriasis	8.02e-06	0.000281	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—TYK2—psoriasis	8e-06	0.000281	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—CAT—psoriasis	7.94e-06	0.000279	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CARM1—psoriasis	7.78e-06	0.000273	CbGpPWpGaD
Fluoxetine—HTR2A—GPCR downstream signaling—CXCL8—psoriasis	7.67e-06	0.000269	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	7.27e-06	0.000255	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—APOE—psoriasis	7.13e-06	0.00025	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—LEP—psoriasis	7.13e-06	0.00025	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—VEGFA—psoriasis	7.07e-06	0.000248	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—CXCL8—psoriasis	6.96e-06	0.000244	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—CAT—psoriasis	6.84e-06	0.00024	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NFKBIA—psoriasis	6.64e-06	0.000233	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—APOE—psoriasis	6.31e-06	0.000222	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—LEP—psoriasis	6.19e-06	0.000217	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—APOE—psoriasis	6.19e-06	0.000217	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—APOE—psoriasis	6.17e-06	0.000217	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—CAT—psoriasis	6.14e-06	0.000216	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CARM1—psoriasis	6e-06	0.000211	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—CAT—psoriasis	5.99e-06	0.00021	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NFKBIA—psoriasis	5.77e-06	0.000202	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—CAT—psoriasis	5.65e-06	0.000198	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—CAT—psoriasis	5.6e-06	0.000197	CbGpPWpGaD
Fluoxetine—CYP2B6—Metabolism—PPARG—psoriasis	5.5e-06	0.000193	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TYK2—psoriasis	5.44e-06	0.000191	CbGpPWpGaD
Fluoxetine—CYP3A5—Metabolism—PPARG—psoriasis	5.37e-06	0.000189	CbGpPWpGaD
Fluoxetine—ALB—Hemostasis—TP53—psoriasis	5.35e-06	0.000188	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—APOE—psoriasis	5.31e-06	0.000187	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—CAT—psoriasis	4.78e-06	0.000168	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—APOE—psoriasis	4.77e-06	0.000167	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—CXCL8—psoriasis	4.74e-06	0.000166	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TYK2—psoriasis	4.72e-06	0.000166	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—APOE—psoriasis	4.66e-06	0.000163	CbGpPWpGaD
Fluoxetine—ALB—Metabolism—PPARG—psoriasis	4.63e-06	0.000163	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling by GPCR—IL6—psoriasis	4.5e-06	0.000158	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—JUN—psoriasis	4.4e-06	0.000155	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—APOE—psoriasis	4.39e-06	0.000154	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—APOE—psoriasis	4.35e-06	0.000153	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—NFKB1—psoriasis	4.24e-06	0.000149	CbGpPWpGaD
Fluoxetine—CYP2C19—Metabolism—PPARG—psoriasis	4.16e-06	0.000146	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—CXCL8—psoriasis	4.11e-06	0.000144	CbGpPWpGaD
Fluoxetine—ABCB1—Metabolism—PPARG—psoriasis	4.06e-06	0.000142	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling by GPCR—IL6—psoriasis	3.91e-06	0.000137	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—VEGFA—psoriasis	3.85e-06	0.000135	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—JUN—psoriasis	3.82e-06	0.000134	CbGpPWpGaD
Fluoxetine—CYP2D6—Metabolism—PPARG—psoriasis	3.82e-06	0.000134	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—STAT3—psoriasis	3.81e-06	0.000134	CbGpPWpGaD
Fluoxetine—CYP2C9—Metabolism—PPARG—psoriasis	3.79e-06	0.000133	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—APOE—psoriasis	3.72e-06	0.00013	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—CAT—psoriasis	3.69e-06	0.00013	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—NFKB1—psoriasis	3.68e-06	0.000129	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—VEGFA—psoriasis	3.34e-06	0.000117	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—STAT3—psoriasis	3.31e-06	0.000116	CbGpPWpGaD
Fluoxetine—CYP1A2—Metabolism—PPARG—psoriasis	3.24e-06	0.000114	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—TP53—psoriasis	2.91e-06	0.000102	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—APOE—psoriasis	2.87e-06	0.000101	CbGpPWpGaD
Fluoxetine—HTR2C—Signaling Pathways—IL6—psoriasis	2.66e-06	9.34e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—TP53—psoriasis	2.52e-06	8.86e-05	CbGpPWpGaD
Fluoxetine—CYP3A4—Metabolism—PPARG—psoriasis	2.5e-06	8.77e-05	CbGpPWpGaD
Fluoxetine—HTR2A—Signaling Pathways—IL6—psoriasis	2.31e-06	8.11e-05	CbGpPWpGaD
